Loading…
SANDOZ ARIPIPRAZOLE is a brand name for Aripiprazole, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Sandoz Aripiprazole (Aripiprazole Tablets) is indicated for: • the treatment of schizophrenia and related psychotic disorders in adults. In controlled clinical trials, Aripiprazole Tablets was found to improve both positive and negative symptoms. Aripiprazole Tablets has been shown to be more effective than placebo in…
Verbatim from this product's HC label. Tap a section to expand.
4 Geriatrics 06/2025 TABLE OF CONTENTS Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. RECENT MAJOR LABEL CHANGES ...........................................................................................
2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .....................................................................
5 1 INDICATIONS .............................................................................................................. 1 Pediatrics.................................................................................................................
2 Geriatrics ................................................................................................................. 7 2. CONTRAINDICATIONS .................................................................................................
7 3. SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 8 4. DOSAGE AND ADMINISTRATION................................................................................. 1 Dosing Considerations ............................................................................................
2 Recommended Dose and Dosage Adjustment ....................................................... 3 Administration ...................................................................................................... 4 Reconstitution .......................................................................................................
5 Missed Dose .......................................................................................................... 12 Sandoz Aripiprazole Page 3 sur 101 Protected B / Protégé B 5. OVERDOSAGE...........................................................................................................
12 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............................... 14 7. WARNINGS AND PRECAUTIONS ................................................................................ 1 Special Populations ...............................................................................................
4 Geriatrics 06/2025 TABLE OF CONTENTS Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed. RECENT MAJOR LABEL CHANGES ...........................................................................................
2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .....................................................................
5 1 INDICATIONS .............................................................................................................. 1 Pediatrics.................................................................................................................
2 Geriatrics ................................................................................................................. 7 2. CONTRAINDICATIONS .................................................................................................
7 3. SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 8 4. DOSAGE AND ADMINISTRATION................................................................................. 1 Dosing Considerations ............................................................................................
2 Recommended Dose and Dosage Adjustment ....................................................... 3 Administration ...................................................................................................... 4 Reconstitution .......................................................................................................
5 Missed Dose .......................................................................................................... 12 Sandoz Aripiprazole Page 3 sur 101 Protected B / Protégé B 5. OVERDOSAGE...........................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Aripiprazole in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
1 Pregnant Women .............................................................................................. 2 Breast-feeding ................................................................................................... 3 Pediatrics...........................................................................................................
4 Geriatrics ........................................................................................................... 5 Use in Patients with Renal Impairment ............................................................ 6 Use in Patients with Hepatic Impairment .........................................................
7 Use in Patients with Concomitant Illness ......................................................... 8 Gender .............................................................................................................. 9 Race ...................................................................................................................
10 Lactose .............................................................................................................. 27 8. ADVERSE REACTIONS................................................................................................
1 Adverse Reaction Overview .................................................................................. 2 Clinical Trial Adverse Reactions ............................................................................ 3 Less Common Clinical Trial Adverse Reactions .....................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.............................................................................................................. 5 Clinical Trial Adverse Reactions (Pediatrics) .........................................................
6 Post-Market Adverse Reactions............................................................................ 57 9. DRUG INTERACTIONS ............................................................................................... 1 Serious Drug Interactions Box...............................................................................
2 Overview ............................................................................................................... 3 Drug-Drug Interactions .........................................................................................
4 Drug-Food Interactions ......................................................................................... 5 Drug-Herb Interactions ......................................................................................... 6 Drug-Laboratory Test Interactions........................................................................
7 Drug-Lifestyle Interactions .................................................................................... 62 10. ACTION AND CLINICAL PHARMACOLOGY […]
12 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............................... 14 7. WARNINGS AND PRECAUTIONS ................................................................................ 1 Special Populations ...............................................................................................
1 Pregnant Women .............................................................................................. 2 Breast-feeding ................................................................................................... 3 Pediatrics...........................................................................................................
4 Geriatrics ........................................................................................................... 5 Use in Patients with Renal Impairment ............................................................ 6 Use in Patients with Hepatic Impairment .........................................................
7 Use in Patients with Concomitant Illness ......................................................... 8 Gender .............................................................................................................. 9 Race ...................................................................................................................
10 Lactose .............................................................................................................. 27 8. ADVERSE REACTIONS................................................................................................
1 Adverse Reaction Overview .................................................................................. 2 Clinical Trial Adverse Reactions ............................................................................ 3 Less Common Clinical Trial Adverse Reactions .....................................................
4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.............................................................................................................. 5 Clinical Trial Adverse Reactions (Pediatrics) .........................................................
6 Post-Market Adverse Reactions............................................................................ 57 9. DRUG INTERACTIONS ............................................................................................... 1 Serious Drug Interactions Box...............................................................................
2 Overview ............................................................................................................... 3 Drug-Drug Interactions .........................................................................................
4 Drug-Food Interactions ......................................................................................... 5 Drug-Herb Interactions ......................................................................................... 6 Drug-Laboratory Test Interactions........................................................................
7 Drug-Lifestyle Interactions .................................................................................... 62 10. ACTION AND CLINICAL PHARMACOLOGY .................................................................. 1 Mechanism of Action […]